People: Mesoblast Ltd (MBLTY.PK)

MBLTY.PK on OTC Markets Group

27.11USD
2:05pm EDT
Price Change (% chg)

$0.16 (+0.59%)
Prev Close
$26.95
Open
$26.87
Day's High
$27.11
Day's Low
$26.87
Volume
840
Avg. Vol
764
52-wk High
$38.60
52-wk Low
$26.26

Search Stocks

Summary

Name Age Since Current Position

Brian Jamieson

 2007 Independent Non-Executive Chairman of the Board

Silviu Itescu

 Executive Director

Jenni Pilcher

 2012 Company Secretary

Eric Rose

 61 2013 Director

Donal O'Dwyer

 59 Non-Executive Director

Michael Spooner

 2007 Non-Executive Director

Ben-Zion Weiner

 68 2012 Non-Executive Director

Julie Meldrum

 IR Contact Officer
» Insider Trading

Biographies

Name Description

Brian Jamieson

 Mr. Brian Jamieson, FCA, has been Independent Non-Executive Chairman of the Board of Mesoblast Ltd since November 22, 2007. He has over 30 years of experience in providing advice and audit services to a diverse range of public and private companies. He was Chief Executive of Minter Ellison, Melbourne, from 2002-2005. Prior to that he was chief executive officer of KPMG Australia from 1998-2000, managing partner of KPMG Melbourne and Southern Regions from 1993-1998, and Chairman of KPMG Melbourne from 2001-2002. He was also a KPMG board member in Australia and a member of the United States management committee. Mr. Jamieson was recently appointed to the position of Non-Executive Chairman of Sigma Pharmaceuticals Limited, having been a Non-executive Director since December 2005. Mr. Jamieson is also a Non-Executive Director of Tatts Group Limited (since May 2005), and Oz Minerals Limited (since August 2004), all of which are ASX listed companies. He is also a Non-Executive Director and Treasurer of the Bionic Ear Institute, and a Director of The Sir Robert Menzies Foundation. He is Fellow of the Institute of Chartered Accountants. He is Member of the Audit & Risk Committee and Member of the Remuneration Committee in the Company.

Silviu Itescu

 Prof. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR, is an Executive Director of Mesoblast Ltd. Professor Itescu has established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He is currently an active faculty member of the University of Melbourne and Monash University and was previously a faculty member of Columbia University in New York. Professor Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of a number of publicly-listed life sciences companies. He is also serving as Director of Mesoblast Inc.

Jenni Pilcher

 Mrs. Jenni Pilcher CA, BBS. has been serving as Company Secretary in Mesoblast Ltd since January 1, 2012. Since qualifying as a Chartered Accountant with Price Waterhouse, she has worked in corporate and business financial roles for high profile international companies in pharmaceuticals, FMCG (fast moving consumer goods) and services. Before joining Mesoblast as Financial Controller in 2007, she spent six years with ASX 200 Company, Spotless Group, progressing through a variety of financial roles. Previously Mrs Pilcher worked in the finance teams at Cadbury Schweppes plc and international pharmaceutical group Medeva plc, both based in the United Kingdom. She was appointed Chief Financial Officer of Mesoblast in November 2007 and Company Secretary in January 2012.

Eric Rose

 Dr. Eric A. Rose, M.D., is Director of Mesoblast Ltd since April 17, 2013. He is currently Chairman and CEO of SIGA Technologies and Executive Vice President, Life Sciences, at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr. Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine, which has a portfolio of research focused on evaluation of complex medical technologies in cardiovascular disease, cancer, diabetes mellitus, and neurologic disease. From 1994 through 2007, Dr. Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 to 1992, he led the Columbia-Presbyterian heart transplantation program, during which time it became the most active program in the United States. Dr. Rose pioneered heart transplantation in children, performing the first pediatric heart transplant in 1984. He is also Chairman of the Board of Circulite, Inc., a developer of advanced left ventricular assist devices.

Donal O'Dwyer

 Mr. Donal P. O'Dwyer, BE, MBA, is Non-Executive Director of Mesoblast Ltd. He has over 20 years' experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, he worked for Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation, initially as its president (Europe) and from 2000 as its worldwide president. In his role, he led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is a qualified civil engineer and has an MBA. He is also serving as Non-executive director in Cochlear Limited, Atcor Medical Holdings Limited and Sunshine Heart Inc., as well as Chairman of Board of Atcor Medical Pty Ltd and Endoluminal Sciences Pty Ltd. He used to serve as Non-executive director of Mesoblast Inc. He is Chairman of the Remuneration Committee and Member of the Audit & Risk Committee in the Company.

Michael Spooner

 Mr. Michael R. Spooner, Bcom, ACA, MAICD, has been a Non-Executive Director of Mesoblast Ltd since November 22, 2007. He is also serving as Chairman of BiVACOR Pty Ltd. He has relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. Mr Spooner consults to a number of listed and unlisted companies based in Australia and the US. In 2009 Mr Spooner was appointed Chairman of BiVACOR a total artificial heart company. Most recently, Mr Spooner was a non-executive director of Peplin Inc., a dermatology focused skin cancer company from 2004 until the company was sold in 2009 for over $300m. He was also a non-executive director of Hawaii Biotech Inc. and Advanced Surgical Design. Previously, Mr Spooner was the Chairman of Mesoblast Limited from its initial listing in 2004 until 2007 and Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australian listed life sciences company into the second highest performing stock on the S&P/ASX 200 index. He also used to serve as Director of Hunter Immunology Limited. He was a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong for several years. He is Chairman of the Audit & Risk Committee and Member of the Remuneration Committee in the Company.

Ben-Zion Weiner

 Dr. Ben-Zion Weiner serves as a Non-Executive Director of Mesoblast Ltd since May 9, 2012. Dr Weiner is Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd. He has been Teva's head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee. In this role, he has directly overseen all pharmaceutical R&D and innovative branded product pipeline development. Dr Weiner has been responsible for the development of hundreds of generic products for the United States, European and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva's innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis. He used to serve as Director of Gefen Biomed Investments Ltd, and was Board Member of XTL Biopharmaceuticals Limited. He is the nominated representative for the Teva Pharmaceutical Industries Ltd board seat.

Julie Meldrum

Basic Compensation

Name Fiscal Year Total

Brian Jamieson

 372,576

Silviu Itescu

 1,521,610

Jenni Pilcher

 310,869

Eric Rose

 --

Donal O'Dwyer

 --

Michael Spooner

 60,000

Ben-Zion Weiner

 --

Julie Meldrum

 --
As Of 29 Jun 2012

Options Compensation

Name Options Value

Brian Jamieson

 0 0

Silviu Itescu

 0 0

Jenni Pilcher

 0 0

Eric Rose

 0 0

Donal O'Dwyer

 0 0

Michael Spooner

 0 0

Ben-Zion Weiner

 0 0

Julie Meldrum

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks